As a positive control of inhibitory efficacy, we verified that the two compounds, even at the lowest doses, consistently reduced viability of non-small cell lung cancer (NSCLC) HCC827 cells that are reported to be sensitive to EGFR TKIs [38] (supplementary Figure S6). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.